Marie_Claude Potier

Dr. Marie_Claude Potier

Institut du Cerveau, Paris, Île-de-France, France
+3

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2009 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
CDCharles Duyckaerts
Charles Duyckaerts
BDBenoît Delatour
Benoît Delatour
MPMarie_Claude Potier
Marie_Claude Potier

20 December 2006 in Bioinformatics
Verified
Journal Article
Open access
PDF file
Isabelle RivalsIsabelle Rivals
Isabelle Rivals
LPLéon Personnaz
Léon Personnaz
LTLieng Taing
Lieng Taing
MPMarie_Claude Potier
Marie_Claude Potier
Motivation: A number of available program packages determine the significant enrichments and/or depletions of GO categories among a class of genes of interest. Whereas a correct formulation of the problem leads to a single exact null distribution, these GO tools use a large variety of statistical tests whose denominations often do not clarify the underlying P-value computations. Summary: We review the different formulations of the problem and the tests they lead to: the binomial, χ2, equality of two probabilities, Fisher's exact and hypergeometric tests. We clarify the relationships existing between these tests, in particular the equivalence between the hypergeometric test and Fisher's exact test. We recall that the other tests are valid only for large samples, the test of equality of two probabilities and the χ2-test being equivalent. We discuss the appropriateness of one- and two-sided P-values, as well as some discreteness and conservatism issues. Contact:isabelle.rivals@espci.fr Supplementary information: Supplementary data are available at Bioinformatics online.

15 March 2016 in Brain
Verified
Journal Article
Open access
PDF file
LHLorraine Hamelin
Lorraine Hamelin
JLJulien Lagarde
Julien Lagarde
GDGuillaume Dorothée
Guillaume Dorothée
CLClaire Leroy
Claire Leroy
MLMickael Labit
Mickael Labit
TTthe Clinical IMABio3 team
the Clinical IMABio3 team
While emerging evidence suggests that neuroinflammation plays a crucial role in Alzheimer’s disease, the impact of the microglia response in Alzheimer’s disease remains a matter of debate. We aimed to study microglial activation in early Alzheimer’s disease and its impact on clinical progression using a second-generation 18-kDa translocator protein positron emission tomography radiotracer together with amyloid imaging using Pittsburgh compound B positron emission tomography. We enrolled 96 subjects, 64 patients with Alzheimer’s disease and 32 controls, from the IMABio3 study, who had both 11C-Pittsburgh compound B and 18F-DPA-714 positron emission tomography imaging. Patients with Alzheimer’s disease were classified as prodromal Alzheimer’s disease (n = 38) and Alzheimer’s disease dementia (n = 26). Translocator protein-binding was measured using a simple ratio method with cerebellar grey matter as reference tissue, taking into account regional atrophy. Images were analysed at the regional (volume of interest) and at the voxel level. Translocator protein genotyping allowed the classification of all subjects in high, mixed and low affinity binders. Thirty high+mixed affinity binders patients with Alzheimer’s disease were dichotomized into slow decliners (n =10) or fast decliners (n =20) after 2 years of follow-up. All patients with Alzheimer’s disease had an amyloid positive Pittsburgh compound B positron emission tomography. Among controls, eight had positive amyloid scans (n = 6 high+mixed affinity binders), defined as amyloidosis controls, and were analysed separately. By both volumes of interest and voxel-wise comparison, 18-kDa translocator protein-binding was higher in high affinity binders, mixed affinity binders and high+mixed affinity binders Alzheimer’s disease groups compared to controls, especially at the prodromal stage, involving the temporo-parietal cortex. Translocator protein-binding was positively correlated with Mini-Mental State Examination scores and grey matter volume, as well as with Pittsburgh compound B binding. Amyloidosis controls displayed higher translocator protein-binding than controls, especially in the frontal cortex. We found higher translocator protein-binding in slow decliners than fast decliners, with no difference in Pittsburgh compound B binding. Microglial activation appears at the prodromal and possibly at the preclinical stage of Alzheimer’s disease, and seems to play a protective role in the clinical progression of the disease at these early stages. The extent of microglial activation appears to differ between patients, and could explain the overlap in translocator protein binding values between patients with Alzheimer’s disease and amyloidosis controls.

16 November 2007 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
CDCharles Duyckaerts
Charles Duyckaerts
MPMarie_Claude Potier
Marie_Claude Potier
BDBenoît Delatour
Benoît Delatour
Animal models aim to replicate the symptoms, the lesions or the cause(s) of Alzheimer disease. Numerous mouse transgenic lines have now succeeded in partially reproducing its lesions: the extracellular deposits of Aβ peptide and the intracellular accumulation of tau protein. Mutated human APP transgenes result in the deposition of Aβ peptide, similar but not identical to the Aβ peptide of human senile plaque. Amyloid angiopathy is common. Besides the deposition of Aβ, axon dystrophy and alteration of dendrites have been observed. All of the mutations cause an increase in Aβ 42 levels, except for the Arctic mutation, which alters the Aβ sequence itself. Overexpressing wild-type APP alone (as in the murine models of human trisomy 21) causes no Aβ deposition in most mouse lines. Doubly (APP × mutated PS1) transgenic mice develop the lesions earlier. Transgenic mice in which BACE1 has been knocked out or overexpressed have been produced, as well as lines with altered expression of neprilysin, the main degrading enzyme of Aβ. The APP transgenic mice have raised new questions concerning the mechanisms of neuronal loss, the accumulation of Aβ in the cell body of the neurons, inflammation and gliosis, and the dendritic alterations. They have allowed some insight to be gained into the kinetics of the changes. The connection between the symptoms, the lesions and the increase in Aβ oligomers has been found to be difficult to unravel. Neurofibrillary tangles are only found in mouse lines that overexpress mutated tau or human tau on a murine tau −/− background. A triply transgenic model (mutated APP, PS1 and tau) recapitulates the alterations seen in AD but its physiological relevance may be discussed. A number of modulators of Aβ or of tau accumulation have been tested. A transgenic model may be analyzed at three levels at least (symptoms, lesions, cause of the disease), and a reading key is proposed to summarize this analysis.

7 January 2015 in The Journal of Neuroscience
Verified
Journal Article
Open access
SMSarah Moyon
Sarah Moyon
ADAnne Laure Dubessy
Anne Laure Dubessy
MAMarie Stephane Aigrot
Marie Stephane Aigrot
MTMatthew Trotter
Matthew Trotter
JHJeffrey K. Huang
Jeffrey K. Huang
CLCatherine Lubetzki
Catherine Lubetzki
The declining efficiency of myelin regeneration in individuals with multiple sclerosis has stimulated a search for ways by which it might be therapeutically enhanced. Here we have used gene expression profiling on purified murine oligodendrocyte progenitor cells (OPCs), the remyelinating cells of the adult CNS, to obtain a comprehensive picture of how they become activated after demyelination and how this enables them to contribute to remyelination. We find that adult OPCs have a transcriptome more similar to that of oligodendrocytes than to neonatal OPCs, but revert to a neonatal-like transcriptome when activated. Part of the activation response involves increased expression of two genes of the innate immune system,IL1β andCCL2, which enhance the mobilization of OPCs. Our results add a new dimension to the role of the innate immune system in CNS regeneration, revealing how OPCs themselves contribute to the postinjury inflammatory milieu by producing cytokines that directly enhance their repopulation of areas of demyelination and hence their ability to contribute to remyelination.

1 September 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EYE. Aït Yahya-Graison
E. Aït Yahya-Graison
JAJ. Aubert
J. Aubert
LDL. Dauphinot
L. Dauphinot
Isabelle RivalsIsabelle Rivals
Isabelle Rivals
MPM. Prieur
M. Prieur
MPMarie_Claude Potier
Marie_Claude Potier